The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
Open accessAbstract
Proteasome inhibition has been validated as a therapeutic modality in the treatment of multiple myeloma and non-Hodgkin's lymphoma. Carfilzomib, an epoxyketone currently undergoing clinical trials in malignant diseases, is a highly selective inhibitor of the chymotrypsin-like (CT-L) activity of the proteasome. A chemistry effort was initiated to discover orally bioavailable analogues of carfilzomib, which would have potential for improved dosing flexibility and patient convenience over intravenously administered agents. The lead compound, 2-Me-5-thiazole-Ser(OMe)-Ser(OMe)-Phe-ketoepoxide (58) (PR-047), selectively inhibited CT-L activity of both the constitutive proteasome (beta5) and immunoproteasome (LMP7) and demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It was well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equivalent to intravenously administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models. The favorable pharmacologic profile supports its further development for the treatment of malignant diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Structure of 20S proteasome from yeast at 2.4Å resolution
Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,257
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Proteolysis: from the lysosome to ubiquitin and the proteasome
Ciechanover, A. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1552 · Cited by 1,133
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 920
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Self-citationOrlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Self-citationRichardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Oral Delivery of Peptide Drugs: Barriers and Developments
Hamman, J. H., Enslin, G. M., & Kotz??, A. F. (2005) · BioDrugs · doi:10.2165/00063030-200519030-00003 · Cited by 499
Kisselev, A. F., Callard, A., & Goldberg, A. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509043200 · Cited by 416
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
Goldberg, A. L. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350012 · Cited by 367
Lonial, S., Waller, E. K., Richardson, P. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1173 · Cited by 340
Protein degradation and the generation of MHC class I-presented peptides
Rock, K. L., York, I. A., Saric, T., & Goldberg, A. L. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80012-8 · Cited by 339
Catalytic Activities of the 20 S Proteasome, a Multicatalytic Proteinase Complex
Orlowski, M., & Wilk, S. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2036 · Cited by 308
Epoxide hydrolases: biochemistry and molecular biology
Fretland, A. J., & Omiecinski, C. J. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00197-6 · Cited by 307
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Groll, M., Heinemeyer, W., Jäger, S., Ullrich, T., Bochtler, M., Wolf, D. H., & Huber, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.10976 · Cited by 300
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. (2000) · Worldwide Protein Data Bank · doi:10.2210/pdb1g65/pdb · Cited by 253
Epoxomicin, a new antitumor agent of microbial origin.
HANADA, M., SUGAWARA, K., KANETA, K., TODA, S., NISHIYAMA, Y., TOMITA, K., YAMAMOTO, H., KONISHI, M., & OKI, T. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.1746 · Cited by 213
Sin, N., Kim, K. B., Elofsson, M., Meng, L., Auth, H., Kwok, B. H. B., & Crews, C. M. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00376-5 · Cited by 207
Eponemycin exerts its antitumor effect through the inhibition of proteasome function.
Meng, L., Kwok, B. H. B., Sin, N., & Crews, C. M. (1999) · PubMed · Cited by 155
Kim, S., Lee, J. I., & Kim, Y. C. (1985) · The Journal of Organic Chemistry · doi:10.1021/jo00205a004 · Cited by 130
Rivett, A. J., & Hearn, A. R. (2004) · Current Protein and Peptide Science · doi:10.2174/1389203043379774 · Cited by 127
Stapnes, C., Døskeland, A. P., Hatfield, K. J., Ersvær, E., Ryningen, A., Lorens, J. B., Gjertsen, B. T., & Bruserud, Ø. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06504.x · Cited by 118
Vinitsky, A., Cardozo, C. P., Sepp‐Lorenzino, L., Michaud, C., & Orłowski, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43960-9 · Cited by 111
Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs.
Harker, W. G., MacKintosh, F. R., & Sikic, B. I. (1983) · PubMed · Cited by 95
Dalton, W. S. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.10.012 · Cited by 39
Novel agents and incremental advances in the treatment of head and neck cancer
Khuri, F. R., & Jain, S. R. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.02.011 · Cited by 28
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Metadata
- Authors
- Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., Lewis, E. R., Lu, Y., Muchamuel, T., Parlati, F., Ring, E., Shenk, K. D., Shields, J., Shwonek, P. J., Stanton, T., Sun, C. M., Sylvain, C., Woo, T. M., & Yang, J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-04-06
- Volume
- 52
- Issue
- 9
- Pages
- 3028-3038
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2033944464
- Cited by
- 272
- References
- 37
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.